Brug af Nivolumab alene eller sammen med Cabozantinib for at forhindre slimhindemelanom tilbage efter operation
Et randomiseret fase II-forsøg med adjuverende nivolumab med eller uden cabozantinib hos patienter med resekeret slimhindemelanom
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Slimhinde melanom
- Anal melanom
- Blære melanom
- Cervikal melanom
- Esophageal melanom
- Galdeblære melanom
- Mundhulens slimhinde melanom
- Penis slimhinde melanom
- Rektalt melanom
- Tilbagevendende slimhindemelanom
- Sinonasal slimhinde melanom
- Urethral melanom
- Vaginalt melanom
- Vulvart melanom
- Hoved- og nakke slimhinde melanom
- Nasopharyngeal slimhinde melanom
- Urinsystemslimhinde melanom
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma.
SECONDARY OBJECTIVES:
I. To compare overall survival between the two adjuvant therapies. II. To evaluate the adverse effects in each arm. III. To assess the correlation between PD-L1 expression in tumor cells with survival (recurrence free survival [RFS] and overall survival [OS]).
IV. To evaluate the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), and OS of nivolumab plus cabozantinib in patients who cannot undergo gross total resection of disease or have metastatic disease at baseline.
V. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
OUTLINE: Patients whose tumor has been fully removed by surgery are randomized to Arm 1 or Arm 2. Patients whose tumor has not been fully removed by surgery or has spread are assigned to Arm 3.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and cabozantinib orally (PO) once daily (QD) of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 3: Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo echocardiogram (ECHO) during screening and as clinically indicated throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months until disease progression, and then every 6 months for up to 5 years from registration or until death.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
-
-
-
California
-
Auburn, California, Forenede Stater, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Forenede Stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Fremont, California, Forenede Stater, 94538
- Palo Alto Medical Foundation-Fremont
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Forenede Stater, 90033
- Los Angeles General Medical Center
-
Modesto, California, Forenede Stater, 95355
- Memorial Medical Center
-
Newport Beach, California, Forenede Stater, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Palo Alto, California, Forenede Stater, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Forenede Stater, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Forenede Stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forenede Stater, 95816
- Sutter Medical Center Sacramento
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Forenede Stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Mateo, California, Forenede Stater, 94401
- Mills Health Center
-
Santa Cruz, California, Forenede Stater, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Forenede Stater, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Forenede Stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Forenede Stater, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Englewood, Colorado, Forenede Stater, 80113
- The Melanoma and Skin Cancer Institute
-
-
Florida
-
Aventura, Florida, Forenede Stater, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Forenede Stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Forenede Stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Forenede Stater, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Forenede Stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forenede Stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Aurora, Illinois, Forenede Stater, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Forenede Stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Forenede Stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Forenede Stater, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Lake Forest, Illinois, Forenede Stater, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Forenede Stater, 60462
- Northwestern Medicine Orland Park
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville, Illinois, Forenede Stater, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Forenede Stater, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Forenede Stater, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forenede Stater, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Forenede Stater, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forenede Stater, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Forenede Stater, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, Forenede Stater, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49009
- Beacon Kalamazoo Cancer Center
-
Muskegon, Michigan, Forenede Stater, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Forenede Stater, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Forenede Stater, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Forenede Stater, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City, Michigan, Forenede Stater, 49684
- Munson Medical Center
-
Wyoming, Michigan, Forenede Stater, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Burnsville, Minnesota, Forenede Stater, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Forenede Stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forenede Stater, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Forenede Stater, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forenede Stater, 55102
- United Hospital
-
-
Missouri
-
Farmington, Missouri, Forenede Stater, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Forenede Stater, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Forenede Stater, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Forenede Stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
-
New York
-
Camillus, New York, Forenede Stater, 13031
- Hematology Oncology Associates of CNY at Camillus
-
East Syracuse, New York, Forenede Stater, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Forenede Stater, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Forenede Stater, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Forenede Stater, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Centerville, Ohio, Forenede Stater, 45459
- Miami Valley Hospital South
-
Cincinnati, Ohio, Forenede Stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Dayton, Ohio, Forenede Stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forenede Stater, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Forenede Stater, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Forenede Stater, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Forenede Stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Forenede Stater, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Forenede Stater, 45429
- Kettering Medical Center
-
Troy, Ohio, Forenede Stater, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Hillman Cancer Center
-
Willow Grove, Pennsylvania, Forenede Stater, 19090
- Asplundh Cancer Pavilion
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- HSHS Sacred Heart Hospital
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Forenede Stater, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Forenede Stater, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Oconto Falls, Wisconsin, Forenede Stater, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay, Wisconsin, Forenede Stater, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
STEP 0 INCLUSION CRITERIA
-
Histologically proven mucosal melanoma by local pathology
-
Central PD-L1 tumor tissue submission
-
STEP 1 INCLUSION CRITERIA
-
Receipt of the central PD-L1 testing results available
- Report is required for randomization of resection R0 or R1 patients
- Testing must be started in Step 0 but results can be reported after registration for resection R2 patients
-
Disease status-Resected R0 or R1 disease patients. Patients eligible for randomization have resected R0 or R1 disease (with negative margins or positive microscopic margins) that must meet one of the following 4 criteria as defined below:
-
Regional lymph node (LN) involvement; OR
-
In-transit metastases/satellite primary disease; OR
-
Single localized, primary disease meeting one of the following site-specific requirements:
-
Head/neck - Sinonasal (including nasopharynx): any primary lesion; Nasal or oral cavity; pT4a or above, given slightly improved OS
- NOTE: Conjunctival: does not meet the qualification for eligibility
-
Anorectal - any primary lesion
-
Vaginal/cervical - any primary, as they have 5 year OS rates of 5-25%
-
Urinary tract - any primary urethral or bladder tumor
-
Penile
-
Vulvar- American Joint Committee on Cancer (AJCC) cutaneous stage IIB or higher
-
Esophageal/gallbladder - any primary
-
-
Locoregionally recurrent following prior resection, meeting at least one of the above criteria
-
In addition, patients must have undergone cross-sectional imaging of the brain, chest, abdomen and pelvis with no evidence of distant metastatic disease
-
-
Disease status-Non-resected R2 or metastatic disease patients
- Non-resected R2 or metastatic disease that is assessable and measurable radiographically or by physical examination
-
Prior Treatment:
- No prior systemic checkpoint inhibitor therapy of mucosal melanoma, including in the adjuvant setting, is allowed. Prior adjuvant chemotherapy or interferon is allowed.
- No other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator. Exceptions may allow for adjuvant no evidence of disease (NED) cancers undergoing hormone based therapy may be eligible pending the other eligibility criteria are met and the principal investigator (PI) affirms the hormonal agent would not change the melanoma response.
- Any radiation must have completed 28 days prior to randomization and the patient must have adequately recovered from its effects.
- For resectable patients only: Surgery must have completed 28 days prior to randomization.
- For resectable patients only: Surgery must have completed no more than 84 days prior to randomization.
-
Not pregnant and not nursing, because this study has an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) >= 50mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Albumin >= 2.8 g/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
-
No cardiovascular disease, including:
- No history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry.
- No history of current class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- No refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg despite adequate attempts at anti-hypertensive therapy.
- No history of myocarditis.
- No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months.
- No corrected QT interval by Fridericia's formula (QTcF) > 500 msec. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard.
-
No underlying hematologic issues, including:
- Congenital bleeding diathesis
- Gastrointestinal (GI) bleeding requiring intervention within the past 6 months, unless directly related to mucosal melanoma
- Active hemoptysis within 42 days prior to study enrollment.
- Active tumor lesions with cavitations or tumor lesions which invade, encase, or abut major blood vessels. The anatomic location and characteristics of primary tumors or metastases as well as the medical history should be carefully reviewed in the selection of subjects for treatment with cabozantinib/placebo.
- Pulmonary emboli or deep vein thromboses (DVT) that require an active anticoagulation regimen.
- No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies.
-
No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics).
-
No known or suspected gastrointestinal disorder affecting absorption of oral medications.
-
Comorbid conditions:
-
No active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
-
No history of autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) or non-infectious pneumonitis.
-
No history of severe allergic reactions to an unknown allergen or any components of the study drugs or its excipients.
-
No history of gastrointestinal perforation or abdominal fistula.
-
No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long as
- The metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND
- The patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND
- The patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to enrollment.
-
No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years.
-
No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction.
-
No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression. Spinal metastases must have completed planned radiation or surgical therapy prior to registration.
-
-
Concomitant medications:
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 5 days prior to the start of study treatment.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 5 days prior to the start of study treatment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Given PO
Andre navne:
Undergo ECHO
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo bone scan
Andre navne:
Undergo blood and tissue sample collection
Andre navne:
|
|
Aktiv komparator: Arm 2 (nivolumab, placebo)
Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo bone scan
Andre navne:
Undergo blood and tissue sample collection
Andre navne:
Given PO |
|
Eksperimentel: Arm 3 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Given PO
Andre navne:
Undergo ECHO
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo bone scan
Andre navne:
Undergo blood and tissue sample collection
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrence free survival (RFS)
Tidsramme: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Will evaluate RFS of single agent adjuvant nivolumab plus placebo compared to the combination treatment of adjuvant nivolumab plus cabozantinib in patients with resected mucosal melanoma. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: Number of days from registration until death (due to any cause, assessed up to 5 years
|
Will be evaluated utilizing the Kaplan-Meier (KM) method and, when appropriate, cox proportional hazards models. Median OS is calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model is built to compare arms 1 and 2 with respect to OS. |
Number of days from registration until death (due to any cause, assessed up to 5 years
|
|
RFS
Tidsramme: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Median RFS will be calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model will also be built to compare arms 1 and 2 with respect to RFS, with and without stratifying for PD-L1 categorization. For non-resected cohort, If a patient in this group has surgery, their RFS data will be censored at the time of surgery. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
|
Progression free survival
Tidsramme: Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
Will be evaluated in multiple settings utilizing the KM method and, when appropriate, cox proportional hazards models. |
Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
|
Objective response rate (Arm 3)
Tidsramme: Up to 5 years
|
Will assess this endpoint utilizing a two-stage Simon that looks to improve from a rate of 20% to 47%. |
Up to 5 years
|
|
Duration of response (Arm 3)
Tidsramme: Time from the first evidence of response until progression, assessed up to 5 years
|
A KM analysis is performed to calculate the median duration of response and 95% confidence intervals are constructed. |
Time from the first evidence of response until progression, assessed up to 5 years
|
|
Incidence of adverse events
Tidsramme: Up to 5 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be summarized. |
Up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Alexander N Shoushtari, Alliance for Clinical Trials in Oncology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Kemiteknikker, analytisk
- Spektrumanalyse
- Nivolumab
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Cabozantinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2021-11794
- U10CA180821 (U.S. NIH-bevilling/kontrakt)
- NCI-2021-11794 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- A091903 (Anden identifikator: CTEP)
- A091903 (Anden identifikator: Alliance for Clinical Trials in Oncology)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .